Company Ticker News March 17, 2022Biogen's Aduhelm Credibility Problem Deepens. Investors Are Paying the Price. 0 0 Share
Press Release March 16, 2022SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB 0 0 Share
Press Release March 16, 2022Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease 0 0 Share
Press Release March 16, 2022Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (BIIB); Lead Plaintiff Deadline is April 8, 2022 0 0 Share
Company Ticker News March 16, 2022Biogen's stock gains after sharing longer term data for its Alzheimer's disease 0 0 Share
Press Release March 16, 2022Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer's Disease in Patients Treated for More Than Two Years 0 0 Share
Press Release March 14, 2022SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB 0 0 Share
Company Ticker News March 14, 2022Advocacy Groups Spending Millions to Influence Decision of Biogen Alzheimer's Treatment 0 0 Share
Press Release March 14, 2022Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference 0 0 Share
